MARKET

CING

CING

Cingulate Inc
NASDAQ
4.180
+0.140
+3.47%
After Hours: 4.010 -0.17 -4.07% 19:04 12/26 EST
OPEN
4.040
PREV CLOSE
4.040
HIGH
4.200
LOW
3.850
VOLUME
155.49K
TURNOVER
--
52 WEEK HIGH
6.01
52 WEEK LOW
3.200
MARKET CAP
28.24M
P/E (TTM)
-0.7815
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CING last week (1215-1219)?
Weekly Report · 5d ago
Roth MKM Reaffirms Their Buy Rating on Cingulate Inc (CING)
TipRanks · 12/16 11:55
Cingulate Inc Reinstates Shane Schaffer as CEO
TipRanks · 12/15 14:28
Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Executive Chairman Of The Board But Will Continue To Serve As Chairman
Benzinga · 12/15 14:21
CINGULATE INC: JOHN ROBERTS WILL NO LONGER SERVE AS EXEC CHAIRMAN BUT WILL CONTINUE TO SERVE AS CHAIRMAN OF BOARD
Reuters · 12/15 14:16
Cingulate Inc. Revises CEO Compensation Terms Following Administrative Leave
Reuters · 12/15 14:15
Weekly Report: what happened at CING last week (1208-1212)?
Weekly Report · 12/15 10:35
Weekly Report: what happened at CING last week (1201-1205)?
Weekly Report · 12/08 10:34
More
About CING
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Webull offers Cingulate Inc stock information, including NASDAQ: CING real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CING stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CING stock methods without spending real money on the virtual paper trading platform.